Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 27, 2014, Pages 9941-9946

  Castro, Jorge ^a   Garcia, Rodrigo I ^a   Kwok, Showming ^a   Banerjee, Abhishek ^a   Petravicz, Jeremy ^a   Woodson, Jonathan ^a   Mellios, Nikolaos ^a   Tropea, Daniela ^b   Sur, Mriganka ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Female mice; Male mice; Molecular therapeutic; Respiration; Synaptic function

Indexed keywords

METHYL CPG BINDING PROTEIN 2; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BREATHING PATTERN; COGNITION; CONTROLLED STUDY; DENDRITIC SPINE; DISEASE SEVERITY; EXCITATORY POSTSYNAPTIC POTENTIAL; EXPLORATORY BEHAVIOR; FEMALE; FUNCTIONAL STATUS; HEART RATE; LIFE EXPECTANCY; LIFESPAN; LOCOMOTION; MALE; MOTOR ACTIVITY; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETT SYNDROME; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR; SYNAPTIC TRANSMISSION; SYSTEMIC THERAPY; VISUAL CORTEX;

FEMALE MICE; MALE MICE; MOLECULAR THERAPEUTIC; RESPIRATION; SYNAPTIC FUNCTION;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; METHYL-CPG-BINDING PROTEIN 2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECOMBINANT PROTEINS; RESPIRATION; RETT SYNDROME; SIGNAL TRANSDUCTION; VISUAL CORTEX;

EID: 84903975689     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1311685111     Document Type: Article

References (58)

1. Banerjee A, Castro J, Sur M (2012) Rett syndrome: Genes, synapses, circuits, and therapeutics. Front Psychiatry 3:34.
2. Chahrour M, Zoghbi HY (2007) The story of Rett syndrome: From clinic to neurobiology. Neuron 56(3):422-437. (Pubitemid 350026269)
3. Chahrour M, et al. (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320(5880):1224-1229. (Pubitemid 351929512)
4. Castro J, Mellios N, Sur M (2013) Mechanisms and therapeutic challenges in autism spectrum disorders: Insights from Rett syndrome. Curr Opin Neurol 26(2):154-159.
5. Tropea D, et al. (2009) Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA 106(6):2029-2034.
6. Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007) Reversal of neurological defects in a mouse model of Rett syndrome. Science 315(5815):1143-1147. (Pubitemid 46328028)
7. Giacometti E, Luikenhuis S, Beard C, Jaenisch R (2007) Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci USA 104(6):1931-1936. (Pubitemid 46239881)
8. Chang Q, Khare G, Dani V, Nelson S, Jaenisch R (2006) The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 49(3):341-348. (Pubitemid 43152236)
9. Zhou Z, et al. (2006) Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 52(2):255-269. (Pubitemid 44548348)
10. Yoshii A, Constantine-Paton M (2010) Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol 70(5):304-322.
11. Ricciardi S, et al. (2011) Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum Mol Genet 20(6):1182-1196.
12. Schmid DA, et al. (2012) A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. J Neurosci 32(5):1803-1810.
13. Wu D, Pardridge WM (1999) Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci USA 96(1):254-259. (Pubitemid 29036086)
14. Nishijima T, et al. (2010) Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron 67(5):834-846.
15. Bondy CA, Cheng CM (2004) Signaling by insulin-like growth factor 1 in brain. Eur J Pharmacol 490(1-3):25-31. (Pubitemid 38482159)
16. Fernandez AM, Torres-Alemán I (2012) The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci 13(4):225-239.
17. Mellios N, et al. (2014) A β-2 adrenergic receptor agonist ameliorates phenotypes and corrects miRNA-mediated IGF1 deficits in an animal model of Rett Syndrome. Proc Natl Acad Sci USA 111:9947-9952.
18. Pini G, et al. (2012) IGF1 as a potential treatment for Rett Syndrome: Safety assessment in six Rett patients. Autism Res Treat 2012:679801.
19. Khwaja OS, et al. (2014) Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci USA 111(12):4596-4601.
20. Marchetto MCN, et al. (2010) A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143(4):527-539.
21. Li Y, et al. (2013) Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 13(4):446-458.
22. Williams EC, et al. (2014) Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons. Hum Mol Genet 23(11):2968-2980.
23. Stearns NA, et al. (2007) Behavioral and anatomical abnormalities in Mecp2 mutant mice: A model for Rett syndrome. Neuroscience 146(3):907-921. (Pubitemid 46694130)
24. Gordon JA, Stryker MP (1996) Experience-dependent plasticity of binocular responses in the primary visual cortex of the mouse. J Neurosci 16(10):3274-3286. (Pubitemid 26142361)
25. Ehrlich I, Malinow R (2004) Postsynaptic density 95 controls AMPA receptor incorporation during long-term potentiation and experience-driven synaptic plasticity. J Neurosci 24(4):916-927. (Pubitemid 38146602)
26. Yoshii A, Sheng MH, Constantine-Paton M (2003) Eye opening induces a rapid dendritic localization of PSD-95 in central visual neurons. Proc Natl Acad Sci USA 100(3):1334-1339. (Pubitemid 36184002)
27. Yoshii A, Constantine-Paton M (2007) BDNF induces transport of PSD-95 to dendrites through PI3K-AKT signaling after NMDA receptor activation. Nat Neurosci 10(6):702-711. (Pubitemid 46828509)
28. Yan H, et al. (2011) Circulating IGF1 regulates hippocampal IGF1 levels and brain gene expression during adolescence. J Endocrinol 211(1):27-37.
29. Ishii T, et al. (2001) The role of different X-inactivation pattern on the variable clinical phenotype with Rett syndrome. Brain Dev 23(Suppl 1):S161-S164.
30. Amir RE, et al. (2000) Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann Neurol 47(5):670-679. (Pubitemid 30261908)
31. Xinhua Bao, et al. (2008) X chromosome inactivation in Rett Syndrome and its correlations with MECP2 mutations and phenotype. J Child Neurol 23(1):22-25.
32. Samaco RC, et al. (2013) Female Mecp2(+/-) mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies. Hum Mol Genet 22(1):96-109.
33. Katz DM, et al. (2012) Preclinical research in Rett syndrome: Setting the foundation for translational success. Dis Model Mech 5(6):733-745, http://dmm.biologists.org/content/5/6/733.long.
34. Weese-Mayer DE, et al. (2006) Autonomic nervous system dysregulation: Breathing and heart rate perturbation during wakefulness in young girls with Rett syndrome. Pediatr Res 60(4):443-449. (Pubitemid 44427598)
35. Viemari J-C, et al. (2005) Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. J Neurosci 25(50):11521-11530. (Pubitemid 43098445)
36. Ogier M, et al. (2007) Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. J Neurosci 27(40):10912-10917. (Pubitemid 47535875)
37. Pitcher MR, et al. (2013) Insulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function. Hum Mol Genet 22(13):2626-2633.
38. Sigmund CD (2000) Viewpoint: Are studies in genetically altered mice out of control? Arterioscler Thromb Vasc Biol 20(6):1425-1429.
39. Leiter EH (2002) Mice with targeted gene disruptions or gene insertions for diabetes research: Problems, pitfalls, and potential solutions. Diabetologia 45(3):296-308.
40. Berglund ED, et al. (2008) Glucose metabolism in vivo in four commonly used inbred mouse strains. Diabetes 57(7):1790-1799.
41. Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 27(3):322-326. (Pubitemid 32201856)
42. Pratte M, Panayotis N, Ghata A, Villard L, Roux J-C (2011) Progressive motor and respiratory metabolism deficits in post-weaning Mecp2-null male mice. Behav Brain Res 216(1):313-320.
43. Ward CS, et al. (2011) MeCP2 is critical within HoxB1-derived tissues of mice for normal lifespan. J Neurosci 31(28):10359-10370.
44. Saenger S, et al. (2011) PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disorders. Growth Horm IGF Res 21(5):292-303.
45. Ciucci F, et al. (2007) Insulin-like growth factor 1 (IGF-1) mediates the effects of enriched environment (EE) on visual cortical development. PLoS ONE 2(5):e475.
46. Derecki NC, Cronk JC, Kipnis J (2013) The role of microglia in brain maintenance: Implications for Rett syndrome. Trends Immunol 34(3):144-150.
47. Feyder M, et al. (2010) Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene variation with phenotypes relevant to autism spectrum disorders and Williams' syndrome. Am J Psychiatry 167(12):1508-1517.
48. Bozdagi O, Tavassoli T, Buxbaum JD (2013) Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay. Mol Autism 4(1):9-12.
49. Shcheglovitov A, et al. (2013) SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature 503(7475):267-271.
50. Noutel J, Hong YK, Leu B, Kang E, Chen C (2011) Experience-dependent retinogeniculate synapse remodeling is abnormal in MeCP2-deficient mice. Neuron 70(1):35-42.
51. Chao H-T, et al. (2010) Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468(7321):263-269.
52. Blackman MP, Djukic B, Nelson SB, Turrigiano GG (2012) A critical and cell-autonomous role for MeCP2 in synaptic scaling up. J Neurosci 32(39):13529-13536.
53. Nguyen MVC, et al. (2012) MeCP2 is critical for maintaining mature neuronal networks and global brain anatomy during late stages of postnatal brain development and in the mature adult brain. J Neurosci 32(29):10021-10034.
54. Cheval H, et al. (2012) Postnatal inactivation reveals enhanced requirement for MeCP2 at distinct age windows. Hum Mol Genet 21(17):3806-3814.
55. Guy J, Cheval H, Selfridge J, Bird A (2011) The role of MeCP2 in the brain. Annu Rev Cell Dev Biol 27:631-652.
56. Cuesto G, et al. (2011) Phosphoinositide-3-kinase activation controls synaptogenesis and spinogenesis in hippocampal neurons. J Neurosci 31(8):2721-2733.
57. Chao H-T, Zoghbi HY, Rosenmund C (2007) MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 56(1):58-65. (Pubitemid 47484176)
58. Landi S, et al. (2011) The short-time structural plasticity of dendritic spines is altered in a model of Rett syndrome. Sci Rep 1:45.